Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint

Benzinga
Ouvrir sur Benzinga